Segment Disclosure - Summary of Net Loss Related To Segment Expenses (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2024	Mar. 31, 2024	Jun. 30, 2025	Jun. 30, 2024
Segment Reporting Information [Line Items]
Collaboration revenue	$ 0		$ 0		$ 7,500	$ 0
Direct external research and development costs	74,985		49,702		136,185	93,952
Personnel-related expenses	22,386		16,053		45,026	30,907
Stock-based compensation expense	13,713		14,716		25,887	24,116
Other research and development costs	2,600		3,163		6,025	6,177
Other general and administrative costs	6,014		5,659		11,545	10,558
Interest income	(7,199)		(10,837)		(15,282)	(22,192)
Other segment items	(2,324)		(343)		(1,932)	(98)
Net loss	(84,706)	$ (65,047)	(57,924)	$ (47,931)	(149,753)	(105,855)
Azetukalner
Segment Reporting Information [Line Items]
Direct external research and development costs	43,405		23,344		74,906	46,557
Pre-clinical, discovery and other programs
Segment Reporting Information [Line Items]
Direct external research and development costs	$ 6,111		$ 6,169		$ 11,078	$ 9,830